Overview
The serotonin pathway, also referred to as the serotonergic system, comprises a network of neurons that synthesize, release, and respond to the neurotransmitter serotonin (5‑hydroxytryptamine, 5‑HT). It is primarily localized in the central nervous system (CNS) but also includes peripheral components such as enterochromaffin cells in the gastrointestinal tract.
Anatomical components
| Structure | Role in the pathway |
|---|---|
| Raphe nuclei (dorsal, median, and other raphe groups in the brainstem) | Major source of serotonergic cell bodies; project axons throughout the forebrain, limbic system, spinal cord, and cerebellum. |
| Forebrain projection areas (e.g., prefrontal cortex, hippocampus, amygdala, striatum) | Receive serotonergic innervation; modulate cognition, mood, memory, and reward processing. |
| Spinal cord | Serotonergic fibers modulate pain perception and autonomic functions. |
| Peripheral organs (e.g., gut, platelets) | Serotonin synthesized by enterochromaffin cells regulates gastrointestinal motility; circulating serotonin stored in platelets influences hemostasis. |
Biosynthesis and metabolism
- Tryptophan (essential amino acid) → 5‑hydroxytryptophan (via tryptophan hydroxylase, the rate‑limiting enzyme).
- 5‑hydroxytryptophan → serotonin (via aromatic L‑amino acid decarboxylase).
- Serotonin is inactivated primarily by monoamine oxidase A (MAO‑A) to 5‑hydroxyindoleacetic acid (5‑HIAA), which is excreted in urine.
Physiological functions
- Mood regulation – Influences affective states; dysregulation is linked to depression and anxiety disorders.
- Sleep–wake cycle – Modulates rapid eye movement (REM) sleep; serotonergic activity generally suppresses REM onset.
- Appetite and satiety – Acts on hypothalamic nuclei to regulate feeding behavior.
- Pain modulation – Inhibits nociceptive transmission at spinal and supraspinal levels.
- Thermoregulation – Participates in body‑temperature control via hypothalamic pathways.
- Cognition and executive function – Affects working memory, decision‑making, and impulse control through prefrontal cortical projections.
Clinical relevance
- Psychiatric disorders – Altered serotonergic signaling is implicated in major depressive disorder, obsessive‑compulsive disorder, and certain anxiety disorders.
- Pharmacotherapy – Selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs), and atypical antipsychotics target components of the serotonin pathway to increase extracellular serotonin levels.
- Migraine – Triptans (5‑HT₁B/₁D agonists) act on serotonergic receptors to abort migraine attacks.
- Irritable bowel syndrome (IBS) – Agents that modulate peripheral serotonin (e.g., 5‑HT₃ antagonists, 5‑HT₄ agonists) are used to treat IBS symptoms.
- Platelet function – Serotonin released from platelets contributes to vasoconstriction during hemostasis; serotonin antagonists can affect bleeding risk.
Receptor subtypes
Serotonin exerts effects through at least 14 receptor subtypes grouped into 7 families (5‑HT₁–5‑HT₇). These are G‑protein‑coupled receptors (all except 5‑HT₃, a ligand‑gated ion channel) and mediate diverse intracellular pathways, including cAMP modulation, phospholipase C activation, and ion fluxes.
Research considerations
- Imaging techniques such as positron emission tomography (PET) with radioligands for the serotonin transporter (SERT) enable in vivo quantification of serotonergic integrity.
- Genetic polymorphisms in the SERT gene (SLC6A4) influence individual responses to serotonergic drugs and susceptibility to mood disorders.
References
(Encyclopedic entries typically include citations; see standard neuroscience and neuropharmacology textbooks for detailed source material.)
